Lv41
536 积分 2022-08-28 加入
Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial
18天前
已完结
Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma
21天前
已完结
The Cost and Financial Burden of Thyroid Cancer on Patients in the US
21天前
已完结
Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib
26天前
已完结
Thyroid Cancer
26天前
已关闭
PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma
26天前
已完结
Divergent Lineage Markers in Anaplastic Thyroid Carcinoma
26天前
已完结
Comprehensive Genomic Profiling of Anaplastic Thyroid Cancer Identifies Alterations in THRA , a Potential Modifier of Cellular Plasticity
26天前
已完结
Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer
26天前
已完结
Thyroid Cancer
26天前
已完结
皖公网安备34019202002308
